Prostatic in Medical Technology

Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale d'Urologie

... drug candidate for the treatment of benign prostatic hypertrophy (BPH), at the 29th Congress of the ... Spectrum is developing ozarelix for benign prostatic hypertrophy (BPH), hormone-dependent prostate cancer and other indications. About Benign prostatic Hypertrophy ...

Vantia Therapeutics' Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia

... markedly with age. It is often the presenting symptom in men with benign prostatic hypertrophy (BPH) and affects at least 70% of BPH patients. There is ... increasing markedly with age. It is often the presenting symptom of benign prostatic hypertrophy (BPH) with at least 70% of BPH patients complaining of ...

Neurocrine Biosciences Presents Elagolix Data

... GnRH antagonist may constitute a new paradigm for the treatment of benign prostatic hyperplasia. About Endometriosis Endometriosis is a painful ... bowel syndrome (IBS), anxiety, depression, pain, diabetes, benign prostatic hyperplasia (BPH) and other neurological and endocrine related diseases ...

Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia

... targets TRPM8 (a transmembrane cation channel protein), to treat benign prostatic hyperplasia (BPH). D-3263 demonstrated the ability to reduce BPH alone ... "Preclinical Evaluation of the TRPM8 Ion Channel Agonist D-3263 for Benign prostatic Hyperplasia" is being presented at the American Urological Association's ...

Gene Found Activated in 70% of Prostate Cancer Cases, George Washington University Medical Center Scientists Report

... "Significant BP1 immunoreactivity was identified in approximately 70% of prostatic adenocarcinomas, whether the analysis was performed on tissue sections (50 ... significantly expressed in prostate adenocarcinoma and is concordant with prostatic intraepithelial neoplasia." The article is also available as "advance ...

Light Sciences Oncology Raises $40.1 Million in Series C Financing

... Metastatic Colorectal Cancer and Phase I/II and Phase IIa Benign prostatic Hyperplasia Studies BELLEVUE, Wash., July 15 /PRNewswire/ -- Light ... multiforme (brain cancer), and early stage clinical trials in benign prostatic hyperplasia (BPH). "We are approaching exciting milestones in the ...

Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder

... safety trial involving silodosin, an investigational treatment for benign prostatic hyperplasia (BPH, or prostate enlargement) and a pharmacokinetic study of ... in the US for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). About Oxybutynin Chloride Topical Gel (OTG) OTG is ...

Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia

... cation channel protein also known as Trp-M8), to treat benign prostatic hyperplasia (BPH). The abstract (#2041), "Preclinical Validation of the Trp-p8 Ion Channel as a Target for Benign prostatic Hyperplasia," is being presented at the American Urological Association's ...

Preventing Prostate Cancer and BPH: Prostate-Health Expert Available (National Men's Health Week Is June 9-15)

... -- The risk of the two major prostate diseases, cancer and benign prostatic hyperplasia (BPH), can be reduced by changes in lifestyle, such as ... have a significantly lower risk of developing symptomatic benign prostatic hyperplasia, or BPH, a condition associated with frequent and painful ...

Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years

... or tamsulosin monotherapy. Enlarged prostate (also known as benign prostatic hyperplasia (BPH)), is a condition that affects 50 percent of men over the ... therapy on lower urinary tract symptoms and Qmax in men with BPH and prostatic enlargement" According to this analysis, the two-year primary endpoint ...

RAPAFLO(TM) (silodosin) Provides Rapid and Sustained Benign Prostatic Hyperplasia (BPH) Symptom Relief in as Little as Three Days

... the University of California at Los Angeles . "The data indicate that RAPAFLO(TM) (silodosin) induces effective relaxation of the targeted prostatic muscle tissue, with a low incidence of vasodilatory and orthostatic effects. RAPAFLO(TM) (silodosin) is a fast acting, effective and safe treatment ...

Study Results Present Paradigm Shift; REDUCE Trial Shows New Hope for the Risk Reduction of Prostate Cancer

... Association annual meeting in Chicago brings optimism to the prostate cancer community as dutasteride (Avodart), a drug used to treat benign prostatic hyperplasia, has shown to lower by 23 percent the risk of prostate cancer in men with an increased risk of the disease. Men's Health Network ...

Data Presented at AUA Demonstrate PROVENGE Significantly Prolongs Survival for Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study

... is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more ...

New Body of Research Suggests Statin Use Benefits Multiple Areas of Urologic Health

... statins and non-steroidal anti-inflammatory drugs (NSAIDs) may further decrease the risk of developing lower urinary tract symptoms related to benign prostatic hyperplasia. "These studies add to a growing body of literature supporting the beneficial effects of statins in certain subsets of patients," ...

Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer

... of Dr. Anthony W. Tolcher. "D3263 is a drug candidate that has potential applicability to multiple types of cancer as well as to benign prostatic hyperplasia (BPH)," stated Mark Frohlich, M.D., senior vice president of clinical affairs and chief medical officer of Dendreon. "The ability of ...

Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IMPACT Trial

... is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more ...

Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)

... today that RAPAFLO (TM) (silodosin), the company's new, uniquely selective alpha blocker for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH), is available for patients by prescription. Watson received U.S. Food and Drug Administration (FDA) approval for RAPAFLO(TM) in ...

Neurocrine Announces Top-Line Results From 702 Study (Lilac PETAL Study) of Elagolix for Treatment of Endometriosis Pain

... candidates address some of the largest pharmaceutical markets in the world including endometriosis, anxiety, depression, pain, diabetes, benign prostatic hyperplasia (BPH), irritable bowel syndrome (IBS) and other neurological and endocrine related diseases and disorders. Neurocrine Biosciences, Inc. ...

Vantia Therapeutics' Pipeline Continues to Mature

... as waking to void at night) is a common condition, with prevalence increasing markedly with age. It is often the presenting symptom of benign prostatic hypertrophy (BPH) with at least 70% of BPH patients complaining of nocturia. Whilst some symptoms of BPH are successfully addressed by the standard ...

Walter Reed Army Medical Center offers HIFU for Qualifying Men with Locally Recurrent Prostate Cancer in a Phase III Clinical Trial

... a transrectal probe to focus ultrasound energy resulting in a therapeutic rise in heat within the prostate. This results in the focal destruction of prostatic tissue. High Intensity Focused Ultrasound does not use radiation and is non surgical. In a small U.S. safety trial, 91 percent of the participants ...

AndroScience Corporation Announces Phase 2a Study Results on ASC-J9(TM) for the Treatment of Acne

... is currently pursuing androgenetic alopecia (male pattern baldness), and wound healing using topical based formulations; and prostate cancer, benign prostatic hyperplasia, and spinal bulbar muscular atrophy (Kennedy's Disease - a neuron motor disease caused by AR mutation) utilizing systemic based ...

Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma

... have implications for patient morbidity and even mortality. LSO has completed a Phase 1/2 trial and has initiated a Phase 2a trial in benign prostatic hyperplasia (BPH), or enlargement of the prostate. The company has positioned itself for growth with a strong portfolio of intellectual property, ...

Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium

... is also developing an orally-available small molecule that targets Trp-p8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more ...

Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial

... Dendreon is also developing an orally-available small molecule called Trp-p8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more ...

Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial

... Dendreon is also developing an orally-available small molecule called Trp-p8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more ...

Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis

... the largest pharmaceutical markets in the world including endometriosis, irritable bowel syndrome (IBS), anxiety, depression, pain, diabetes, benign prostatic hyperplasia (BPH) and other neurological and endocrine related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available ...

Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October

... Dendreon is also developing an orally-available small molecule called Trp-p8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more ...

Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery

... Dendreon is also developing an orally-available small molecule called Trp-p8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more ...

Neurocrine Biosciences Completes 'Petal Study' Treatment Phase for Endometriosis

... the largest pharmaceutical markets in the world including endometriosis, irritable bowel syndrome (IBS), anxiety, depression, pain, diabetes, benign prostatic hyperplasia (BPH) and other neurological and endocrine related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available ...

BN ImmunoTherapeutics Starts Clinical Trials With Prostate Cancer Vaccine

... on the company's MVA-BN(R) technology, is designed to generate cellular and humoral immune responses to PSA and PAP (prostate specific antigen and prostatic acid phosphatase), which are both well-known prostate cancer tumor targets. Prostate cancer is, along with breast cancer, in the top three ...

Neurocrine Biosciences Reports First Quarter 2008 Results

... the largest pharmaceutical markets in the world including endometriosis, irritable bowel syndrome (IBS), anxiety, depression, pain, diabetes, benign prostatic hyperplasia (BPH) and other neurological and endocrine related diseases and disorders. Indiplon was licensed from DOV Pharmaceuticals in 1998. ...

Microwave Treatments for Enlarged Prostate Cause Blood Pressure Surges

... pressure surges of the magnitude identified in this study are troubling side effects of treatment that need to be monitored and managed." Benign prostatic hyperplasia (BPH), or an enlarged prostate gland, is a condition affecting half of men over age 50 and 80 percent of those over 70. Symptoms include ...

Dong-A PharmTech Co., Ltd. Announces Portal Hypertension Clinical Trial With Udenafil

... is continuing its development of udenafil for erectile dysfunction in the USA and will develop udenafil for other indications such as benign prostatic hyperplasia and pulmonary hypertension." Ms. Ursula Falk, Managing Director of Dr. Falk Pharma commented, "Our partnership with Dong-A PharmTech ...

Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia

... (FDA). Watson is seeking marketing approval of silodosin from the FDA for the treatment of the signs and symptoms associated with benign prostatic hyperplasia (BPH), or enlarged prostate. Watson anticipates that the FDA will take action on its application in the fourth quarter 2008. Silodosin ...

Prostate Cancer Treatment Centre Receives Funding for Clinical Trials

... Canadian data on HIFU therapy." HIFU has been used in several countries for a number of years to treat men with localized prostate cancer and benign prostatic hyperplasia. The therapy uses ultrasound energy to heat and destroy specifically targeted areas of the prostate. HIFU was approved for use in the ...

Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development

... T315I mutant, which is generally refractory to other Src and Aurora Kinase inhibitors," said Mousses. Antitumor activity of brostallicin on human prostatic cancer: role of combination with hypomethylating agents (Abstract #A288) Data were presented that show brostallicin, when combined ...

'Use it or Lose it': A New Theory About Preserving Erectile Function After Prostate Surgery

... covered in the 48-page report: -- Alternative therapies for prostate cancer -- Handling a prostate cancer relapse -- Surgical options for benign prostatic hyperplasia A year's subscription to Perspectives on Prostate Disease is available for $99 (for print and electronic versions; $89 for electronic ...

Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at Annual Meeting of American Urological Association

... drug candidate for the treatment of benign prostatic hypertrophy (BPH), at the American ... Spectrum is developing ozarelix for benign prostatic hypertrophy (BPH), hormone-dependent prostate cancer and other indications. About Benign prostatic Hypertrophy ...

AEterna Zentaris' Partner, Spectrum, Discloses Detailed Phase 2 Data for Ozarelix, in BPH at Annual AUA Meeting

... (LHRH/GnRH) antagonist, ozarelix, in benign prostatic hyperplasia (BPH). Results indicate that ... lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH)" reviewed results of a ... in the Japanese oncology market. About Benign prostatic Hyperplasia ...